Response to Ophthalmic Market Boom Gives Rise to New Technique
June 14, 2011 - Since its inception, Charles River Pathology Associates has been developing a core team of experienced histology technicians to conduct specialized eye studies. Over the years, we have launched many programs to improve the efficiency and quality of eye section production.
One such program gave rise to a new technique: the use of tumor marker dye at tissue trimming. Shown to increase the visibility of the optic nerve within the block, this technique allows small rodent eyes to be embedded intact, thereby reducing artifact. At the same time, the use of tumor marker dye results in a significant reduction in the number of recuts for the optic nerve - without a loss of productivity.
In all, this technique reduces the time required to obtain a high-quality sagittal section in rodent eyes, thereby increasing both efficiency and quality.
Ophthalmic Market Report
This all came about in response to a report issued in 2007, titled “Global Ophthalmic Market Analysis & Forecasts to 2012.” This report stated that from 2007 to 2012 the global ophthalmic pharmaceutical market would experience a compound annual growth rate of 11.11%. Seeking a strong position for this growing market, Charles River Pathology Associates began looking for pathologists with particular expertise in ocular pathology.
With additions to the staff, and various program initiations, the contribution of studies having an ocular delivery route or involving intraocular devices grew considerably.
Charles River Pathology Associates’ Experience and Capabilities
With a dedicated plastics lab and standard paraffin lab, Charles River Pathology Associates can produce either ground or thin sections of devices in situ. We also have a specialized immunopathology laboratory capable of developing immunohistochemical staining methods using both client-provided and commercial antibodies and/or antibody-based products as required. Other capabilities include tissue cross-reactivity (TCR) studies, biodistribution studies and biomarker work - all of which can be GLP or non-GLP, depending on the client's needs.
In just the past two years, this group has processed and read over 80 ocular studies, including large animal studies involving medical devices (e.g., artificial retina, glaucoma shunts), intravitreal therapies to target macular degeneration as well as topical treatments for dry eye. Others include ocular phototoxicity studies in rats and several large-scale rodent studies looking at the use of stem cell therapies in the eye.
For more information about the use of tumor marker dye at tissue trimming, or the services offered by Charles River Pathology Associates, please contact us at firstname.lastname@example.org.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 28–Jun 01
The International Bone and Mineral Society (IBMS) and the Japanese Society for Bone and Mineral Research (JSBMR) are excited to sponsor the second joint scientific meeting by the two organizations.
May 27–May 29
Charles River and the René Remie Surgical Skills Centre (RRSSC) have joined their expertise and are pleased to offer a 3-day surgery training course. Held at the RRSSC in the Netherlands, this training is designed to be very practical and combines lectures with hands-on exercises, ensuring you receive the most comprehensive training experience. This course is recommended for simple procedures only (e.g., simple exeresis, simple catheterizations such as jugular vein or femoral vein, simple ALZET pump implantation, ECG radiotelemetry).
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.